title: Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
abstract: Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disorder of the central nervous system, caused by the reactivation of the ubiquitous JC virus. PML usually occurs during severe immunosuppression, and the most common causes are represented by human immunodeficiency virus infection, lymphoproliferative disorders and other forms of cancer. Recently, the introduction of monoclonal antibodies (e.g. natalizumab, rituximab, efalizumab) in the treatment of several dysimmune diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis and systemic lupus erythematosus, has led to an increased incidence of PML. This phenomenon has had severe consequences, leading, for example, to the withdrawal from the market of Efalizumab, and important restrictions in the use of the other compounds, all of which are characterized by high efficacy in improving prognosis and quality of life. In this review we will discuss clinical, laboratory and imaging findings of PML. In addition, proposed pathogenetic mechanisms promoting the reactivation of JC virus in the context of treatment with monoclonal antibodies will be described.
authors.affiliation: Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
authors.forename: E
authors.initials: E
authors.lastname: Tavazzi
authors.forename: P
authors.initials: P
authors.lastname: Ferrante
authors.forename: K
authors.initials: K
authors.lastname: Khalili
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D009103:Multiple Sclerosis / Q000188:drug therapy; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology; D011565:Psoriasis / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents
references.citation: J Med Virol. 2008 Dec;80(12):2147-52
references.pmid: 19040292
references.citation: J Infect Dis. 2010 Jul 15;202(2):184-91
references.pmid: 20550458
references.citation: Blood. 2009 May 14;113(20):4834-40
references.pmid: 19264918
references.citation: Arch Dis Child. 1992 Jul;67(7):956-7
references.pmid: 1325756
references.citation: Infection. 2003 Dec;31(6):374-8
references.pmid: 14735377
references.citation: Ann Neurol. 2004 Mar;55(3):320-8
references.pmid: 14991809
references.citation: Lancet Infect Dis. 2009 Oct;9(10):625-36
references.pmid: 19778765
references.citation: Blood. 2002 Feb 15;99(4):1486-8
references.pmid: 11830505
references.citation: J Neurol Neurosurg Psychiatry. 2002 May;72(5):653-6
references.pmid: 11971057
references.citation: Gastroenterology. 2000 Nov;119(5):1228-35
references.pmid: 11054380
references.citation: N Engl J Med. 1961 Oct 26;265:815-23
references.pmid: 14038684
references.citation: Scand J Infect Dis. 2003;35(11-12):909-10
references.pmid: 14723382
references.citation: AJNR Am J Neuroradiol. 1986 Nov-Dec;7(6):1033-5
references.pmid: 3098066
references.citation: Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7484-9
references.pmid: 10377441
references.citation: Expert Opin Drug Saf. 2011 Mar;10(2):239-51
references.pmid: 21214420
references.citation: N Engl J Med. 2005 Jul 28;353(4):362-8
references.pmid: 15947080
references.citation: Arch Neurol. 2006 Oct;63(10):1383-7
references.pmid: 17030653
references.citation: N Engl J Med. 2005 Jul 28;353(4):369-74
references.pmid: 15947079
references.citation: N Engl J Med. 2006 Mar 2;354(9):924-33
references.pmid: 16510746
references.citation: Lancet. 1971 Jun 19;1(7712):1257-60
references.pmid: 4104715
references.citation: Lancet Neurol. 2010 Mar;9(3):264-72
references.pmid: 20117055
references.citation: Radiology. 1993 Apr;187(1):233-40
references.pmid: 8451420
references.citation: Arch Dermatol. 2009 Aug;145(8):937-42
references.pmid: 19687432
references.citation: J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):26-31
references.pmid: 18667930
references.citation: Oncologist. 2010;15(11):1214-9
references.pmid: 21041380
references.citation: J Virol. 1998 Dec;72(12):9918-23
references.pmid: 9811728
references.citation: N Engl J Med. 2005 Jul 28;353(4):375-81
references.pmid: 15947078
references.citation: J Infect Dis. 1993 Jan;167(1):13-20
references.pmid: 8380288
references.citation: Neuroepidemiology. 2010;35(3):178-84
references.pmid: 20664291
references.citation: Arch Neurol. 2011 Sep;68(9):1156-64
references.pmid: 21555606
references.citation: Brain. 1958 Mar;81(1):93-111
references.pmid: 13523006
references.citation: Neurology. 1999 Jan 15;52(2):253-60
references.pmid: 9932940
references.citation: Arch Neurol. 2009 Aug;66(8):1021-4
references.pmid: 19667225
references.citation: J Infect Dis. 2009 Mar 15;199(6):881-8
references.pmid: 19434914
references.citation: Ann Neurol. 2005 Apr;57(4):576-80
references.pmid: 15786466
references.citation: Cancer. 2005 Feb 1;103(3):516-27
references.pmid: 15630684
references.citation: Lupus. 2005;14(12):964-6
references.pmid: 16425577
references.citation: AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1896-906
references.pmid: 10588116
references.citation: Ann Neurol. 2008 Oct;64(4):379-87
references.pmid: 18688812
references.citation: Arch Neurol. 2008 Sep;65(9):1162-5
references.pmid: 18779418
references.citation: Mult Scler. 2011 Feb;17(2):151-6
references.pmid: 21078695